SynthesisBMC cancer2026
Risk factors for pulmonary metastases in osteosarcoma: a systematic review and meta-analysis.
Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary metastases are the leading cause of mortality in osteosarcoma patients. Identifying high-risk factors is essential for optimizing surveillance and treatment. To systematically review and analyze clinical and pathological risk factors associated with pulmonary metastases in osteosarcoma.
methodsA systematic digital screening of PubMed, Scopus, and EMBASE was carried out without restrictions, supplemented by manual and grey literature searches. Observational studies reporting odds ratios (ORs) with 95% confidence intervals (CIs) for pulmonary metastases were included. A qualitative and quantitative analysis was carried out by pooling the effect estimates using forest plots. The quality of the studies was assessed by the Newcastle- Ottawa scale.
resultsFifteen studies involving over 12,000 patients were included. In univariate analyses, larger tumor size, positive N stage, higher T stage, and treatment with radiation or chemotherapy were significantly associated with increased risk of lung metastasis, whereas surgery was associated with reduced risk. Patients aged 18–40 years showed a lower risk in univariate analysis, while gender and tumor location were not significantly associated. In multivariate analyses, tumor size greater than 10 cm, positive N stage, higher histologic grade (particularly Grades III and IV), and advanced T stage remained independent predictors of lung metastasis. Age and gender were not independently associated after adjustment. Surgery continued to demonstrate a protective association, whereas radiation and chemotherapy were associated with increased odds of lung metastasis.
conclusionTumor size, stage, nodal status, and histological grade are strong predictors of pulmonary metastases in osteosarcoma, while surgery is protective. These findings support the use of risk-stratified follow-up and further research on integrating molecular markers into prognostic models. PROSPERO REGISTRATION: CRD420251053452.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.